For patients with acute myeloid leukemia (AML) receiving intensive chemotherapy, AML-SCORE and PINA-Score help to estimate 1) complete remission and early death rate in patients ≥60 years and 2) probabilities of overall and relapse-free survival in patients with AML with normal karyotype.
SAL Study Alliance Leukemia
AMLCG

References

1. Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J,
 Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann BJ,
 Hiddemann W, Ehninger G, Berdel WE, Büchner T and Müller-Tidow C. Complete remission and early death
 after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes. Lancet 2010; 376(9757): 2000-2008. Download this Document (PDF-File)

2. Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J,
Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C,
Lengfelder E, Sauerland MC, Heinecke A, Wörmann B and Hiddemann W. Age-related risk profile
and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid
Leukemia Cooperative Group. J Clin Oncol 2009; 27(1): 61-69.

3. Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J,
 Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC,
 Heinecke A, Wörmann B and Hiddemann W. Double induction containing either two courses or one course
of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell
transplantation or prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24(16): 2480-2489.

4. Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry K, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland C, Heinecke A, Krug U, Berdel WE, Buechner T, Wörmann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD, and Hoster E. A combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal AML (PINA). J Clin Oncol 2014; [Epub ahead of print]. Download this Document (PDF-File)

5. Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo Coco F, Pelicci PG, Martelli MF, and GIMEMA Acute Leukemia Working Party. N Engl J Med. 2005; 352(3): 254–266.

6. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, and Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996; 10(12): 1911–1918.

7. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, and Tenen DG. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-[alpha] (C/EBP[alpha]), in acute myeloid leukemia. Nat Genet. 2001; 27(3): 263–270.

8. Snaddon J, Smith ML, Neat M, Cambal-Parrales M, Dixon-McIver A, Arch R, Amess JA, Rohatiner AZ, Lister TA, Fitzgibbon J. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer. 2003; 37(1): 72-78.

9. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649-655.